首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1560843

全球寡核苷酸合成市场 - 2024 - 2031

Global Oligonucleotide Synthesis Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

报告概述

2023年全球寡核苷酸合成市场规模达75亿美元，预计2031年将达152亿美元，2024-2031年预测期间复合年增长率为9.0%

寡核苷酸合成是产生短核苷酸序列（称为寡核苷酸）的化学程序，用于分子生物学、生物技术和治疗应用。这些合成的 DNA 或 RNA 链用于遗传分析、诊断和治疗。这项技术的进步带来了个人化医疗、基于 RNA 的疫苗和遗传疾病的标靶治疗。由于基因组学、生物製药和诊断学的创新，合成寡核苷酸市场持续扩大。

市场动态：

驱动程式和限制

增加对製药和生技公司的投资

寡核苷酸合成市场受到政府资金和研究的大量投资的推动，促进了创新和治疗探索。然而，成本侵蚀和缺乏标准化指南等挑战构成了潜在的障碍。因此，利害关係人必须驾驭这些市场动态，以在不久的将来充分利用市场的成长潜力。

例如，2024 年6 月，GSK plc 宣布以高达5,000 万美元（约3,900 万英镑）的价格收购了Elsie Biotechnologies，这是一家总部位于圣地亚哥的私人生物技术公司，致力于释放寡核苷酸疗法的全部潜力。寡核苷酸具有调节基因表现的独特能力，使其成为解决大部分传统小分子或生物製剂无法解决的治疗标靶的一种有吸引力的方式。

成本侵蚀

由于成本侵蚀、治疗性寡核苷酸指南的不确定性以及缺乏统一指南，寡核苷酸合成市场面临挑战。这些因素可能会影响利润率和市场可持续性，阻碍寡核苷酸合成技术的无缝发展。对于产业利害关係人来说，有效应对这些挑战对于分子诊断和临床应用的持续成长至关重要。

细分市场分析

全球寡核苷酸合成市场根据产品类型、应用、最终用户和地区进行细分。

该产品类型细分市场的试剂约占寡核苷酸合成市场份额的41.3%

产品类型细分市场的试剂占比约41.3%。全球寡核苷酸合成市场严重依赖试剂，包括亚磷酰胺、溶剂、催化剂和封端剂，它们控制合成过程的效率、准确性和产量。高品质试剂可确保寡核苷酸链的保真度并最大限度地减少错误。由于基因编辑、诊断和治疗领域对精确可靠的寡核苷酸的需求不断增长，合成试剂市场已显着扩大。基于寡核苷酸的研究的成功和新型疗法的开发与试剂品质的进步直接相关。

例如，2024年9月，Emp Biotech与Atom Scientific合作，在英国和爱尔兰分销其高品质寡核苷酸合成试剂，标誌着该公司寡核苷酸合成产品的独家分销合作伙伴关係。

市场地域占有率

预计北美在整个预测期内将占据总市场份额的 38.4% 左右

由于生命科学和医疗保健领域的研发投资不断增加，以及对开发各种疾病的个人化疗法的日益关注，北美预计将在整个预测期内占据总市场份额的38.4% 左右，这是支撑该市场巨大份额的主要因素。

例如，2024 年 5 月，领先的酶工程公司 Codexis, Inc. 宣布，它透过酶途径成功合成了寡核苷酸，以支持基于 RNA 的治疗药物的生产。 Codexis 首次透过连接缀合部分从起始材料酵素合成全长寡核苷酸，为 RNAi 治疗产业的替代製造方法提供了重要的製程证明。

此外，美国癌症协会预测，到2024年，美国将有2,001,140例新癌症病例和611,720例癌症相关死亡。增长。合成寡核苷酸用于各种研究和诊断应用。

Oligonucleotide synthesis is the chemical process of creating short nucleotide sequences, known as oligonucleotides, for molecular biology, biotechnology, and therapeutic applications. These synthetic DNA or RNA strands are used in genetic analysis, diagnostics, and therapeutics. Advancements in this technology have led to personalized medicine, RNA-based vaccines, and targeted therapies for genetic diseases. The market for synthetic oligonucleotides continues to expand due to innovations in genomics, biopharmaceuticals, and diagnostics.

Market Dynamics: Drivers & Restraints

Increased investment in pharmaceutical and biotechnology companies

The oligonucleotide synthesis market is boosted by substantial investment from government funds and research, promoting innovation and therapeutic exploration. However, challenges like cost erosion and lack of standardized guidelines pose potential hindrances. Therefore, stakeholders must navigate these market dynamics to fully capitalize on the market's growth potential in the near future.

For instance, in June 2024, GSK plc announced that it had acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics, for up to $50 million (approximately £39 million). Oligonucleotides have a unique ability to modulate gene expression, making them an attractive modality to address a significant proportion of therapeutic targets that are not amenable to traditional small molecules or biologics.

Erosion of costs

The oligonucleotide synthesis market faces challenges due to cost erosion, uncertainty in therapeutic oligo guidelines, and a lack of unified guidelines. These factors could impact profit margins and market sustainability, hindering the seamless progression of oligonucleotide synthesis technologies. It is crucial for industry stakeholders to effectively address these challenges for sustained growth in molecular diagnostics and clinical applications.

Market Segment Analysis

The global oligonucleotide synthesis market is segmented based on product type, application, end-user, and region.

The reagents from the product type segment accounted for approximately 41.3% of the oligonucleotide synthesis market share

The reagents from the product type segment accounted for approximately 41.3%. The global oligonucleotide synthesis market relies heavily on reagents, including phosphoramidites, solvents, catalysts, and capping agents, which control the efficiency, accuracy, and yield of the synthesis process. High-quality reagents ensure the fidelity of oligonucleotide chains and minimize errors. The market for synthesis reagents has expanded significantly due to the growing demand for precise and reliable oligonucleotides in gene editing, diagnostics, and therapeutics. The success of oligonucleotide-based research and the development of novel therapeutics are directly linked to reagent quality advancements.

For instance, in September 2024, Emp Biotech partnered with Atom Scientific to distribute its high-quality oligonucleotide synthesis reagents in the UK and Ireland, marking an exclusive distribution partnership for the company's oligonucleotide synthesis products.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to increasing R&D investments in the field of life sciences and healthcare and the growing focus on developing personalized therapeutics for various diseases are major factors supporting the large share of this market.

For instance, in May 2024, Codexis, Inc. a leading enzyme engineering company, announced it successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Codexis has achieved the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety, providing a significant proof of process for alternative manufacturing methods in the RNAi therapeutics industry.

Moreover, the American Cancer Society predicts that in the year 2024, there will be 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. As the demand for new and improved cancer treatments increases, the requirement for synthetic oligonucleotides is growing. The synthetic oligonucleotides are used in a variety of research and diagnostic applications.

Market Segmentation

By Product Type

Reagents

Equipment

Synthesized Oligonucleotides

Oligonucleotide-based drugs

Primers

Probes

Large-scale synthesized oligonucleotides

Others

By Application

Research

PCR

QPCR

Sequencing

Gene Synthesis

Others

Diagnostics

Therapeutics

DNA & Oligonucleotide-based therapies

RNAi Oligonucleotide-based therapies

CpG Oligonucleotide-based therapies

By End User

Hospitals

Academic & Research Institutes

Pharmaceutical & Biotechnology companies

Diagnostic Laboratories

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Thermo Fisher Scientific Inc., Agilent Technologies Inc., Integrated DNA Technologies (IDT), LGC Biosearch Technologies, Bio-Synthesis Inc., GE Healthcare (Cytiva), Eurofins Genomics, TriLink BioTechnologies (a Maravai LifeSciences company), Merck KGaA (Sigma-Aldrich), ATDBio Ltd among others.

Key Developments

In May 2024, Molecular Assemblies, Inc. a pioneer and leader in the field of enzymatic DNA synthesis, announced the launch of its Partnering Program to license Molecular Assemblies' Fully Enzymatic SynthesisTM (FESTM) technology for onsite synthesis. FES technology accelerates the production of long, pure, and accurate DNA to power a new rapidly emerging generation of therapeutics and diagnostics.

In March 2023, Ansa successfully synthesized a 1005-base-long oligonucleotide with industry-leading accuracy, marking a significant advancement in oligonucleotide synthesis. The company launched an Early Access Program for clonal synthetic genes in April 2023 to assist researchers in obtaining challenging sequences, such as the 1005 base sequence for gene therapy development, which is highly complex and requires the assembly of shorter oligonucleotides.

Why Purchase the Report?

To visualize the global oligonucleotide synthesis market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the oligonucleotide synthesis market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global oligonucleotide synthesis market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increased investment in pharmaceutical and biotechnology companies
  - 4.1.1.2. Advancements in the research and development
- 4.1.2. Restraints
  - 4.1.2.1. Erosion of costs
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Reagents*
- 6.2.1. Introduction
6.3. Equipment
6.4. Synthesized Oligonucleotides

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.2. Market Attractiveness Index, By Application
7.3. Research*
- 7.3.1. Introduction
- 7.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.4. Diagnostics
7.5. Therapeutics

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Academic & Research Institutes
8.4. Pharmaceutical & Biotechnology companies
8.5. Diagnostic Laboratories

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Thermo Fisher Scientific Inc*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Agilent Technologies Inc.
11.3. Integrated DNA Technologies (IDT)
11.4. LGC Biosearch Technologies
11.5. Bio-Synthesis Inc.
11.6. GE Healthcare (Cytiva)
11.7. Eurofins Genomics
11.8. TriLink BioTechnologies (a Maravai LifeSciences company)
11.9. Merck KGaA (Sigma-Aldrich)
11.10. ATDBio Ltd. (*LIST NOT EXHAUSTIVE)